New Report Finds Investing in Global Health R&D Delivers Returns at Home and Abroad
The investment case for global health R&D is increasingly evidence-based. Impact Global Health’s new Ripple Effect analysis tracks what happens […]
News
New Study Finds Investing in Shorter, More Effective TB Treatment Pays Off
A new analysis, published in IJTLD Open, from South Africa and the Philippines further confirms that six-month, all-oral BPaL/M regimens
TB Alliance Welcomes WHO Prequalification of Lupin’s Pretomanid Product
NEW YORK (September 12, 2025)—Lupin Limited, a leading pharmaceutical company headquartered in India, has been granted prequalification by the World
TB Alliance Appoints Dr. Soraya Madani as Senior Vice President, Program and Alliance Management
New York, NY (August 29, 2025) – TB Alliance announced the appointment of Dr. Soraya Madani as Senior Vice President,
TB Alliance Congratulates Dr. Kathleen Schostack on Her Retirement
As Senior Vice President of Program and Alliance Management, Dr. Schostack played a vital role in advancing TB drug development
Realizing our “Triple-A Mandate”
Four years ago, TB Alliance secured the first regulatory approval from the United States Food and Drug Administration (US FDA)
TB Alliance Issues Call for Researchers to Access TB Biomarker Repository
NEW YORK (March 23, 2021) – Interested researchers are invited to apply to access the MARK-TB (Markedly Accelerating Research with
Results of Phase 2B Clinical Trial Testing New Drug-Resistant TB Treatment Published in Lancet Respiratory Medicine
November 13, 2019 – Results of the Phase 2B trial, known as NC-005 have been published in The Lancet Respiratory Medicine.
TB Alliance Welcomes Global Drug Facility’s Listing of Pretomanid
The Stop TB Partnership’s Global Drug Facility (GDF) has added the anti-TB drug pretomanid to its catalog of TB medicines.
TB Alliance and Macleods Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB
NEW YORK and MUMBAI (October 28, 2019)—Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to